DE60329839D1 - Behandlung und verhütung von gewebeschäden, die mit erhöhter produktion von c-reactivem protein verbunden sind - Google Patents
Behandlung und verhütung von gewebeschäden, die mit erhöhter produktion von c-reactivem protein verbunden sindInfo
- Publication number
- DE60329839D1 DE60329839D1 DE60329839T DE60329839T DE60329839D1 DE 60329839 D1 DE60329839 D1 DE 60329839D1 DE 60329839 T DE60329839 T DE 60329839T DE 60329839 T DE60329839 T DE 60329839T DE 60329839 D1 DE60329839 D1 DE 60329839D1
- Authority
- DE
- Germany
- Prior art keywords
- reactive protein
- prevention
- treatment
- tissue damage
- ligands
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108010074051 C-Reactive Protein Proteins 0.000 title abstract 5
- 102100032752 C-reactive protein Human genes 0.000 title abstract 5
- 230000002265 prevention Effects 0.000 title 1
- 230000000451 tissue damage Effects 0.000 title 1
- 231100000827 tissue damage Toxicity 0.000 title 1
- 239000003446 ligand Substances 0.000 abstract 7
- 108010045517 Serum Amyloid P-Component Proteins 0.000 abstract 2
- 102100036202 Serum amyloid P-component Human genes 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pathology (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0211136.7A GB0211136D0 (en) | 2002-05-15 | 2002-05-15 | Treatment and prevention of tissue damage |
PCT/GB2003/002096 WO2003097104A1 (en) | 2002-05-15 | 2003-05-14 | Treatment and prevention of tissue damage |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60329839D1 true DE60329839D1 (de) | 2009-12-10 |
Family
ID=9936726
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60329839T Expired - Lifetime DE60329839D1 (de) | 2002-05-15 | 2003-05-14 | Behandlung und verhütung von gewebeschäden, die mit erhöhter produktion von c-reactivem protein verbunden sind |
Country Status (11)
Country | Link |
---|---|
US (1) | US7615543B2 (de) |
EP (1) | EP1503800B1 (de) |
JP (2) | JP2005531559A (de) |
AT (1) | ATE446761T1 (de) |
AU (1) | AU2003234000B8 (de) |
CA (1) | CA2485852C (de) |
DE (1) | DE60329839D1 (de) |
DK (1) | DK1503800T3 (de) |
ES (1) | ES2333522T3 (de) |
GB (1) | GB0211136D0 (de) |
WO (1) | WO2003097104A1 (de) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0211136D0 (en) * | 2002-05-15 | 2002-06-26 | Univ London | Treatment and prevention of tissue damage |
US7763256B2 (en) | 2002-12-23 | 2010-07-27 | William Marsh Rice University | Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation |
EP1576368B1 (de) | 2002-12-23 | 2009-02-18 | William Marsh Rice Univeristy | Verfahren und verbindungen zur verstärkung der fybrozyten-bildung |
US8012472B2 (en) | 2002-12-23 | 2011-09-06 | William Marsh Rice University | Compositions and methods for suppressing fibrocytes |
GB0313386D0 (en) * | 2003-06-10 | 2003-07-16 | Univ London | Treatment of disease |
WO2005070409A1 (en) * | 2004-01-21 | 2005-08-04 | Medvet Science Pty Ltd | A method of modulating pro-inflammatory and inflammatory activity mediated by c-reactive protein |
EP1582527A1 (de) * | 2004-03-31 | 2005-10-05 | Ciba SC Holding AG | Synthese von phosphorbasierenden Liganden |
CA2654440C (en) * | 2005-06-06 | 2013-09-03 | Girish J. Kotwal | Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury |
ES2409756T3 (es) | 2006-12-04 | 2013-06-27 | Promedior, Inc. | Combinación de SAP y de enalapril para su uso en tratamiento de trastornos fibróticos o fibroproliferativos |
US8497243B2 (en) | 2007-07-06 | 2013-07-30 | Promedior, Inc. | Methods and compositions useful in the treatment of mucositis |
US9884899B2 (en) | 2007-07-06 | 2018-02-06 | Promedior, Inc. | Methods for treating fibrosis using CRP antagonists |
ES2684493T3 (es) | 2009-03-11 | 2018-10-03 | Promedior Inc. | Un polipéptido SAP para uso en el tratamiento de trastornos autoinmunitarios y enfermedad del injerto contra el huésped |
AU2010224170B2 (en) | 2009-03-11 | 2015-12-24 | Promedior, Inc. | Treatment and diagnostic methods for hypersensitive disorders |
UA110323C2 (en) | 2009-06-04 | 2015-12-25 | Promedior Inc | Derivative of serum amyloid p and their receipt and application |
EP2987803B1 (de) | 2009-06-17 | 2018-08-29 | Promedior Inc. | Sap-varianten und deren verwendung |
CN102725345B (zh) | 2009-09-18 | 2014-12-10 | 陶氏环球技术有限责任公司 | 用于凝塑成形工艺的粉末热塑性聚烯烃弹性体组合物 |
WO2011155956A1 (en) | 2010-06-08 | 2011-12-15 | Dow Global Technologies Llc | Polyolefin elastomer composition for artificial leather applications |
WO2013090524A1 (en) * | 2011-12-14 | 2013-06-20 | The Texas A&M University System | Compositions associated with and methods of managing neutrophil movement using serum amyloid p (sap) |
US9332953B2 (en) | 2012-08-31 | 2016-05-10 | The University Of Chicago | Supervised machine learning technique for reduction of radiation dose in computed tomography imaging |
EP2957563A1 (de) * | 2014-06-19 | 2015-12-23 | Pentracor GmbH | Trennmaterial mit Phosphorylcholinderivaten |
GB202002299D0 (en) | 2020-02-19 | 2020-04-01 | Pentraxin Therapeutics Ltd | Agents for use in the treatment of tissue damage |
WO2021197371A1 (zh) * | 2020-03-31 | 2021-10-07 | 南京金斯瑞生物科技有限公司 | 一种含有刚性连接子的生物偶联物 |
WO2022178594A1 (en) * | 2021-02-25 | 2022-09-01 | Baker Heart and Diabetes Institute | C-reactive protein inhibitors |
GB202111866D0 (en) | 2021-08-18 | 2021-09-29 | Ucl Business Plc | Prodrugs for use in the treatment of tissue damage |
KR20230060368A (ko) * | 2021-10-27 | 2023-05-04 | 솔브레인 주식회사 | 환형 포스핀 화합물의 제조방법 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4640913A (en) | 1983-01-10 | 1987-02-03 | American Cyanamid Company | Phosphocholine derivatives having antihypertensive action |
IL84252A (en) | 1987-10-23 | 1994-02-27 | Yissum Res Dev Co | Phospholipase inhibiting compositions |
US5681829A (en) | 1992-10-08 | 1997-10-28 | Shaman Pharmaceuticals, Inc. | Class of phosphocholine derivatives having antifungal activity |
US5811568A (en) | 1992-10-08 | 1998-09-22 | Shaman Pharmaceuticals, Inc. | Process for the preparation of mono- and bis(phosphocholine) derivatives which have antifungal activity |
JP4524846B2 (ja) | 2000-04-20 | 2010-08-18 | 日油株式会社 | 化粧料 |
US6764826B2 (en) | 2000-06-08 | 2004-07-20 | Board Of Regents, The University Of Texas System | Inhibitors of C-reactive protein induced inflammation |
US7390795B2 (en) * | 2000-12-18 | 2008-06-24 | Pentraxin Therapeutics Limited | Treatment and prevention of tissue damage |
EP1418905B1 (de) * | 2001-08-08 | 2007-05-02 | Pentraxin Therapeutics Limited | Wirkstoff zur entfernung einer unerwünschten proteinpopulation aus dem plasma |
GB0211136D0 (en) * | 2002-05-15 | 2002-06-26 | Univ London | Treatment and prevention of tissue damage |
-
2002
- 2002-05-15 GB GBGB0211136.7A patent/GB0211136D0/en not_active Ceased
-
2003
- 2003-05-14 AU AU2003234000A patent/AU2003234000B8/en not_active Ceased
- 2003-05-14 CA CA2485852A patent/CA2485852C/en not_active Expired - Fee Related
- 2003-05-14 ES ES03727670T patent/ES2333522T3/es not_active Expired - Lifetime
- 2003-05-14 DK DK03727670.6T patent/DK1503800T3/da active
- 2003-05-14 AT AT03727670T patent/ATE446761T1/de not_active IP Right Cessation
- 2003-05-14 WO PCT/GB2003/002096 patent/WO2003097104A1/en active Application Filing
- 2003-05-14 DE DE60329839T patent/DE60329839D1/de not_active Expired - Lifetime
- 2003-05-14 EP EP03727670A patent/EP1503800B1/de not_active Expired - Lifetime
- 2003-05-14 US US10/514,127 patent/US7615543B2/en not_active Expired - Fee Related
- 2003-05-14 JP JP2004505099A patent/JP2005531559A/ja not_active Ceased
-
2010
- 2010-02-04 JP JP2010022669A patent/JP2010174013A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US7615543B2 (en) | 2009-11-10 |
US20060019930A1 (en) | 2006-01-26 |
GB0211136D0 (en) | 2002-06-26 |
CA2485852C (en) | 2012-01-17 |
ATE446761T1 (de) | 2009-11-15 |
AU2003234000A1 (en) | 2003-12-02 |
EP1503800A1 (de) | 2005-02-09 |
EP1503800B1 (de) | 2009-10-28 |
CA2485852A1 (en) | 2003-11-27 |
DK1503800T3 (da) | 2010-02-01 |
WO2003097104A1 (en) | 2003-11-27 |
JP2010174013A (ja) | 2010-08-12 |
AU2003234000B2 (en) | 2008-06-05 |
AU2003234000B8 (en) | 2008-07-31 |
JP2005531559A (ja) | 2005-10-20 |
ES2333522T3 (es) | 2010-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60329839D1 (de) | Behandlung und verhütung von gewebeschäden, die mit erhöhter produktion von c-reactivem protein verbunden sind | |
EA200801172A1 (ru) | Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения | |
MX2018016320A (es) | Moleculas de union que se unen a (pd-l1) y (lag-3). | |
WO2021163064A3 (en) | Antibodies and fusion proteins that bind to ccr8 and uses thereof | |
DE69942578D1 (de) | Bifunktionelle moleküle sowie darauf basierende therapien. | |
EA200301117A1 (ru) | Антитела против vla-1 | |
DK3085783T3 (da) | Bispecifikt antistof som substitution for funktionelle proteiner | |
EA200801521A1 (ru) | Лиганды, которые обладают специфичностью связывания к vegf и/или egfr, и способы их применения | |
EA200602044A1 (ru) | Молекулярно впечатанные полимеры, селективные по отношению к нитрозаминам, и способы их применения | |
WO2007015107A3 (en) | Artificial platelets | |
EA200200105A1 (ru) | СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ PPARγ; | |
EP2221317A3 (de) | Pegylierte Single-domain-Antikörper (dAb) | |
DE69942565D1 (de) | Therapeutische mittel welche einen bispezifischen anti-hla class ii invariant chain x anti-pathogen antikörper enthalten | |
ATE425186T1 (de) | Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften | |
EA200400063A1 (ru) | Антитела к опг лиганду | |
WO2006129843A3 (en) | Bispecific capturing molecule | |
WO2008143666A3 (en) | Crystal structures of neuropilin fragments and neuropilin-antibody complexes | |
EP3339327A3 (de) | Antikörper gegen unlösliches fibrin | |
WO2002050122A3 (en) | Means for the diagnosis and therapy of ctcl | |
DE60310400D1 (de) | Botulinustoxine zur behandlung von priapismus | |
WO2003071269A3 (en) | Methods and apparatuses for characterizing stability of biological molecules | |
ATE363214T1 (de) | Löslicher natamycin-proteinkomplex | |
ATE207932T1 (de) | Komplexe aus porphyrin und menschlichem serumalbumin mit der fähigkeit, sauerstoff zu binden, und deren therapeutische verwendungen | |
ATE540967T1 (de) | Verfahren zur reinigung von proteinen | |
NO20025738D0 (no) | Metode |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |